Drugmaker Vivus said patients who took its weight loss drug Qsymia were more than 70 percent less likely to develop type 2 diabetes compared to patients who took a placebo. The data comes from a group of patients who participated in a late-stage clinical trial of Qsymia. Those patients were at high risk for developing diabetes: they had prediabetes or a group of symptoms called metabolic syndrome, which includes high blood pressure, large waist size, and inability to handle glucose.
Help employers find you! Check out all the jobs and post your resume.
